Blog Part 1    Blog Part 3

Unlock the full potential of your samples with our blog series on nucleic acid extraction.

In this series, we dive into the essentials of DNA and RNA purification – from choosing the right extraction method and reagents to troubleshooting common challenges. Each post offers practical tips, comparisons of technologies, and real-world application insights to help you streamline your workflow and get reliable results, every time. Stay tuned and follow along to make your nucleic acid extraction smarter, faster, and more consistent.

Most labs have seen qPCR curves that simply “don’t feel right”. Very often, the explanation lies upstream in the extraction.

How extraction impacts qPCR and RT‑qPCR

Ct shifts and poor amplification efficiency are classic signs of residual inhibitors.
Ethanol, guanidinium, detergents, and phenol can directly reduce polymerase activity, leading to delayed Cts, low plateau phases, and inconsistent amplification between replicates. Another frequent problem is artificial fold changes: differences in lysis efficiency or inhibitor removal between samples can change apparent target abundance even when the underlying biology is identical.

For example, if heme or other blood components are removed more efficiently from one set of samples than another, apparent “expression differences” may be entirely technical.

False negatives are particularly common for low copy targets.
Mild degradation or partial inhibition disproportionately affect these assays. A marginally extracted or slightly inhibited sample may be called negative even though target molecules are present.

In RT‑qPCR, genomic DNA contamination can further blur the picture. If DNase treatment is incomplete and assays are not intron‑spanning, genomic DNA can generate signal that masquerades as mRNA expression—a serious problem for low expression targets and pseudogene‑rich regions.

To make qPCR truly quantitative rather than semi‑qualitative:

• Treat input requirements realistically.
• Use spectrophotometric ratios (A260/280, A260/230) as plausibility checks, not as the sole quality criteria.
• In RNA workflows, implement a validated DNase strategy and RT‑minus controls on at least a subset of samples.
• For complex matrices (blood, stool, soil, plants), use extraction protocols explicitly tuned for inhibitor removal or add a dedicated cleanup step before qPCR.

When extraction is designed thoughtfully, qPCR becomes a genuinely quantitative tool instead of a convenient screening assay with unstable sensitivity.

How extraction impacts NGS and RNA‑seq

Sequencing magnifies extraction problems: what is subtle in qPCR becomes obvious at the scale of millions of reads.

In DNA‑based NGS (WGS, targeted panels, exomes), extraction quality drives:

• Library complexity and duplication rates
• Coverage uniformity
• Performance in GC‑rich or otherwise challenging regions

Low or biased DNA input leads to over‑amplification of a small subset of fragments. You see high duplicate levels and poor effective coverage, especially in GC‑rich regions. Extraction chemistries that preferentially recover certain fragment sizes or GC contents distort coverage, complicating variant calling, CNV analysis, and any depth‑based interpretation.

Fragment size is another critical parameter. Over‑sheared or heavily nicked DNA limits read length on long‑read platforms and undermines assembly or structural variant detection. Even for short‑read WGS, a suboptimal size distribution can reduce library construction efficiency. Damage introduced or exacerbated during extraction—oxidation, depurination, crosslinking in FFPE samples—can create artifacts that look like true low‑frequency variants.

In RNA‑seq, extraction leaves distinct fingerprints:

• Degradation creates strong transcript length bias, under‑representing long transcripts and skewing differential expression and pathway analyses.
• Incomplete lysis of certain cell types in tissues or microbiome samples introduces cell‑type or organism bias, where some transcriptomes are under‑represented or absent.
• Genomic DNA contamination inflates transcript counts and complicates isoform and intron–exon analyses.
• Residual inhibitors interfere with reverse transcription, end repair, adapter ligation, and amplification, yielding low‑yield libraries, skewed size distributions, and high QC failure rates.

For both DNA and RNA sequencing, extraction quality sets the upper limit on performance. No bioinformatic correction can fully compensate for fundamentally compromised input.

In the final part of this series, we will look at sample‑type specific pitfalls, pre‑analytical variables, and practical levers at the bench—plus how to design extractions backwards from qPCR and NGS to make your workflow more robust without starting from scratch.